Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
Zevra Therapeutics (NasdaqGS: ZVRA) will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, via news release after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, via news release after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
According to Zevra, the live webcast and a 90-day replay will be available on the “Events & Presentations” page in the Investor Relations section of investors.zevra.com. Investors can also join via telephone using U.S. dial-in (800) 274-8461, international dial-in +1 (203) 518-9814, and Conference ID ZVRAQ226.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ZVRA
On Jul 22, the day this news came out, ZVRA closed 2.49% below the previous close. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 22 session.
Key Figures
- Results Report Date
- August 5, 2026
- Second quarter 2026 corporate and financial results
- Conference Call Time
- 4:30 p.m. ET
- August 5, 2026 results call
- Replay Availability
- 90 days
- Webcast replay availability
- Replay Start Time
- Approximately 5:30 p.m. ET
- August 5, 2026 webcast replay
Previous Earnings Reports
-
Revenue growth, asset sale, debt prepayment, and pipeline progress accompanied negative share reaction.
-
Scheduled first-quarter results release and conference call details preceded a positive reaction.
-
Revenue, net income, cash, and pipeline updates preceded a 21.27% positive reaction.
-
Scheduled fourth-quarter and full-year results call preceded a positive reaction.
-
Revenue growth, reduced loss, cash, and pipeline progress preceded a negative reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the second quarter on Wednesday, August 5, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
To join via telephone, please use the following dial-in information:
- (800) 274-8461 (United States)
- +1 (203) 518-9814 (International)
- Conference ID: ZVRAQ226
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.